Additionally, we identified that DNA damage repair‐related drugs such as Bleomycin and Gemcitabine; EGFR inhibitors such as Lapatinib and Pazopanib; PI3K/mTOR inhibitors such as Rapamycin, Shikonin, and temsirolimus; Bcl‐2 inhibitors such as Obatoclax and TW.37; as well as MEK inhibitors such as CI.1040 and RDEA119 with relatively lower IC50 values might also be treatment options for high‐risk CC patients. This evidence concerns the gene EGFR and cholangiocarcinoma.